comparemela.com

Gopa Iyer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dr Bochner on Bladder-Sparing Regimens in MIBC

Bernard H. Bochner, MD, FACS, discusses ongoing studies evaluating the potential bladder-sparing options for patients with muscle-invasive bladder cancer.

Bernardh bochnerGopa iyerMemorial sloan kettering cancer centerInterdisciplinary prostate cancer congressAnnual interdisciplinary prostate cancer congressEducation resourceMemorial sloan kettering cancerUrothelial cancerOnclive tv

Neoadjuvant and Adjuvant Trials Could Continue to Individualize Treatment in MIBC

Bernard H. Bochner, MD, FACS, discusses updates in the treatment of muscle-invasive bladder cancer and ongoing trials in the space.

New yorkUnited statesBernardh bochnerMurrayf brennanGopa iyerSurgery at memorial sloan kettering cancer centerInterdisciplinary prostate cancer congressSir murrayMemorial sloan kettering cancer centerAnnual interdisciplinary prostate cancer congressEducation resource17th annual interdisciplinary prostate cancer congress and other genitourinary malignanciesAlliance a031701 trial nct03609216

Flare Therapeutics Presents FX-909 Phase 1 Dose Escalation and Expansion Clinical Trial Design at the 2024 ASCO Genitourinary Cancers Symposium

/PRNewswire/ Flare Therapeutics Inc., a biotechnology company targeting transcription factors (TF) to discover precision medicines for cancer and other.

United statesUnited kingdomSan franciscoMichaell meyersGopa iyerPrnewswire flare therapeutics incMoscone west conference centerMemorial sloane kettering cancer centerGenitourinary oncologist early drug development specialistTherapeutics incCancers symposiumChief medical officerGenitourinary oncologistEarly drug development specialistMemorial sloane kettering cancerExpansion study

Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium

/PRNewswire/ Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients.

United statesSan franciscoGopa iyerAmerican society of clinical oncologyPrnewswire aadi bioscience incAadi bioscience incFoundation medicineClinical oncologyGenitourinary cancers symposiumRenal cell cancerAadi bioscienceHealth care amp hospitalsMedical pharmaceuticalsTrade show newsClinical trials amp medical discoveries

Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Two new real-world next-generation sequencing studies reinforce prevalence of TSC1/2 mutations in up to 2% of all tumors, a significant addressable cancer population PRECISION1 tumor-agnostic trial.

United statesBrian mcmorranMarcy grahamShihe houAndrew kwonMaria zalathGopa iyerSean wallaceKhine nyein myintNormaa palmaIgor vivancoWillish navarroAadi bioscienceFoundation medicinePrnewswire aadi bioscience incCompany annual report on form

vimarsana © 2020. All Rights Reserved.